Current Clinical Practice: Acute Myeloblastic Leukemia: Management with High-Dose Cytosine Arabinoside, Daunorubicin and Marrow Transplantation

References

• Priesler, H., Davis, R. B., Kirshner, J., Dupre, E., Richards III, F., Hoagland, H. C., Kopel, S., Levy, R. N., Carey, R., Schulman, P., Gottlieb, A. J. and McIntyre, O. R., and the Cancer and Leukemia Group B (1987). Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study, Blood, 69, 1441.
   PubMed Web of Science ®Google Scholar
• Arlin, Z., Case, D. C. Jr., Moore, J., Wiernik, P., Feldman, E., Saletan, S., Desai, P., Sia, L. and Cartwright, K., and the Lederle Cooperative Group (1990). Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL), Leukemia, 4, 177.
   PubMed Web of Science ®Google Scholar
• Cassileth, P. A., Lynch, E., Hines, J. D., Oken, M. M., Mazza, J. J., Bennett, J. M., McGlave, P. B., Edelstein, M., Harrington, D. P. and O'Connell, M. J. (1992). Varying intensity of postremission therapy in acute myeloid leukemia, Blood, 79, 1924.
   PubMed Web of Science ®Google Scholar
• Schiller, G., Gajewski, J., Territo, M., Nimer, S., Lee, M., Belin, T. and Champlin, R. (1992). Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia, Blood, 80, 2977.
   PubMed Web of Science ®Google Scholar
• Ghaddar, H. M., Plunkett, W., Kantarjian, H. M., Pierce, S., Freireich, E. J., Keating, M. J. and Estey, E. H. (1994). Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside, Leukemia, 8, 1269.
   PubMed Web of Science ®Google Scholar
• Mitus, A. J., Miller, K. B., Schenkein, D. P., Ryan, H. F., Parsons, S. K., Wheeler, C. and Antin, J. H. (1995). Improved survival for patient with acute myelogenous leukemia, J Clin Oncol, 13, 560.
   PubMed Web of Science ®Google Scholar
• Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R. and Frei III, E., for the Cancer and Leukemia Group B (1994). Intensive postremission chemotherapy in adults with acute myeloid leukemia, N Engl J Med, 331, 896.
   PubMed Web of Science ®Google Scholar
• Zittoun, R. A., et al. (1995). Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia, N Engl J Med, 322, 217.
   Google Scholar
• Cassileth, P. A., Andersen, J., Lazarus, H. M., Colvin, O. M., Bennett, J. M., Stadtmauer, E. A., Kaizer, H., Weiner, R. S., Edelstein, M. and Oken, M. M. (1993). Autologous bone marrow transplant in acute myeloid leukemia in first remission, J Clin Oncol, 11, 314.
   PubMed Web of Science ®Google Scholar
• Estey, E. (1996). Treatment of refractory AML, Leukemia, 10, 932.
   PubMed Web of Science ®Google Scholar
• Liso, V., Iacopino, P., Avvisati, G., Petti, M. C., Broccia, G., Carotenuto, M., Falda, M., Fazi, P., Lazzarino, M., Leoni, P., Mirto, S., Pucci, G., Nobile, F., Nosari, A. M., Speccia, G., Stasi, R., Tabilo, A. and Mandelli, F., for the GIMEMA Group (1996). Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients, Leukemia, 10, 1443.
   PubMed Web of Science ®Google Scholar
• Mehta, J., Powles, R., Horton, C., Milan, S., Treleaven, J., Tait, D. and Catovsky, D. (1994). Bone marrow transplantation for primary refractory acute leukemia, Bone Marrow Transpl, 14, 415.
   PubMed Web of Science ®Google Scholar
• Stasi, R., Venditti, A., Del Poeta, G., Aronica, G., Abruzzese, E., Pisani, F., Cecconi, M., Masi, M. and Amadori, S. (1996). High-dose chemotherapy in adult acute myeloid leukemia: rationale and results, Leukemia Res, 20, 535.
   PubMed Web of Science ®Google Scholar
• Curtis, J. E., Messner, H. A., Minden, M. D., Minkin, S. and McCulloch, E. A. (1987). High-dose cytosine arabinoside in the treatment of acute myelogenous leukemia: contributions to outcome of clinical and laboratory attributes, J Clin Oncol, 5, 532.
   PubMed Web of Science ®Google Scholar
• Curtis, J. E., Messner, H. A., Minden, M. D., Lipton, J. H., Lockwood, G. A., Tritchler, D. L. and McCulloch, E. A. (1992). High-dose cytosine arabinoside remission induction for acute myelogenous leukemia: comparison of two regimens of remission maintenance, Leukemia, 11, 1192.
   Google Scholar
• Bishop, J. F., Mathews, J. P., Young, G. A., Szer, J., Gillett, A., Joshua, D., Bradstock, K., Enno, A., Wolf, M. M., Fox, R., Cobcroft, R., Herrmann, E., Van Der Weyden, M., Lowenthal, R. M., Page, F., Garson, O. M. and Juneja, S. (1996). A randomized study of high-dose cytarabine in induction in acute myeloid leukemia, Blood, 87, 1710.
   PubMed Web of Science ®Google Scholar
• Weick, J. K., Kopecky, K. J., Appelbaum, F. R., Head, D. R., Kingsbury, L. L., Balcerzak, S. P., Bickers, J. N., Hynes, H. E., Welborn, J. L., Simon, S. R. and Grever, M. (1996). A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloidleukemia: a southwest oncology group study, Blood, 88, 2841.
   PubMed Web of Science ®Google Scholar
• Brinker, H. (1985). Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission, Cancer Treat Rep, 69, 5.
   PubMedGoogle Scholar
• Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paciucci, P. A., Schulman, P., Lee, E. J., Moore, J. O., Powell, B. L. and Schiffer, C. A., for the Cancer and Leukemia Group B (1995). Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia, N Engl J Med, 332, 1671.
   PubMed Web of Science ®Google Scholar
• Dombret, H., Chastang, C., Fenaux, P., Reiffers, J., Bordessoule, D., Bouabdallah, R., Mandelli, F., Ferrant, A., Auzanneau, G., Tilly, H., Yver, A. and Degos, L., for the AML Cooperative Study Group (1995). A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia, N Engl J Med, 332, 1678.
   PubMed Web of Science ®Google Scholar
• Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R. and Sultan, C. (1985). Proposed revised criteria for the classification of acute myeloid leukemia, Ann Intern Med, 103, 620.
   PubMed Web of Science ®Google Scholar
• Rees, J. K. (1990). Chemotherapy of the leukemias. In Freireich E. J., ed. New approaches to the treatment of leukemia, Berlin: Springer-Verlag, 5–77.
   Google Scholar
• Kaplin, E. L. and Meier, P. (1958). Non-parametric estimation for incomplete observations, J Am Stat Assoc, 53, 457.
   Web of Science ®Google Scholar
• Kalbfleisch, J. D. and Prentice, R. L. (1980). The statistical analysis of failure time data, New York, John Wiley & Sons, Inc., 16.
   Google Scholar
• Clift, R. A., Buckner, C. D., Appelbaum, F. R., Schock, G., Petersen, F. B., Bensinger, W. I., Sanders, J., Sullivan, K. M., Storb, R., Singer, J., Hansen, J. A. and Thomas, E. D. (1992). Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia, J Clin Oncol, 10, 1723.
   PubMed Web of Science ®Google Scholar
• Brown, R. A., Wolff, S. N., Fay, J. W., Pineiro, L., Jr. Collins, R. H., Lynch, J. P., Stevens, D., Greer, J., Herzig, R. H. and Herzig, G. P. (1995). High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American marrow transplant group, Blood, 85, 1391.
   PubMed Web of Science ®Google Scholar
• Peterson, F. B., Lynch, M. H. E., Clift, R. A., Appelbaum, F. R., Sanders, J. E., Bensinger, W. I., Benyunes, M. C., Doney, K., Fefer, A., Martin, P., Storb, R., Rowley, S., Sullivan, K. M., Witherspoon, R., Weiden, P. and Thomas, E. D. (1993). Autologous marrow transplantation for patients with acute myeloid leukemia in untreated first relapse or in second complete remission, J Clin Oncol, 11, 1353.
   PubMed Web of Science ®Google Scholar
• Moore, J. O., Dodge, R. K., Amrein, P. C., Kolitz, J., Lee, E. J., Powell, B., Godfrey, S., Robert, F. and Schiffer, C. A. (1997). Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022, Blood, 89, 780.
   PubMed Web of Science ®Google Scholar
• Hann, I. M., Stevens, R. F., Goldstone, A. H., Rees, J. K. H., Wheatley, K., Gray, R. G. and Burnett, A. K., on behalf of the adult and childhood working parties of the Medical Research Council. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia, Results of the Medical Research Council's 10th AML trial (MRC AML10). Blood, 89, 2311.
   PubMed Web of Science ®Google Scholar
• Reiffers, J., Stoppa, A. M., Attal, M., Michallet, M., Marit, G., Blaise, D., Huguet, F., Corront, B., Cony-Makhoul, P., Gastaut, J. A., Laurent, G., Molina, L., Broustet, A., Maraninchi, D., Pris, J., Hollard, D. and Faberes, C., for the BGMT Group 1996. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study, Leukemia, 10, 1874.
   PubMed Web of Science ®Google Scholar
• Gale, R. P., Buchner, T., Zhang, M-J., Heinecke, A., Champlin, R. E., Dicke, K. A., Gluckman, E., Good, R. A., Gratwohl, A., Herzig, R. H., Keating, A., Klein, J. P., Marmont, A. M., Prentice, H. G., Rowlings, P.A., Sobocinski, K. A., Speck, B., Weiner, R. S. and Horowitz, M. (1996). HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission, Leukemia, 10, 1687–1691.
   PubMed Web of Science ®Google Scholar
• Ferrant, A., Labopin, M., Frassoni, F., Prentice, H. G., Cahn, J. Y., Blaise, D., Reiffers, J., Visani, G., Sanz, M. A., Boogaerts, M. A., Lowenberg, B. and Gorin, N. C., on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (1997). Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation Study, Blood, 90, 2921.
   PubMed Web of Science ®Google Scholar
• Proctor, S. J., Taylor, P. R. A., Stark, A., Carey, P. J., Bown, N., Hamilton, P. J. and Reid, M. M., on behalf of the Northern Regional Haematology Group (1995). Evaluation of the impact of allogeneic transplant in first remission on an unselected population of patients with acute myeloid leukemia aged 15–55 years, Leukemia, 9, 1246.
   PubMed Web of Science ®Google Scholar
• Freireich, E. J. (1990). The impact of cytogenetics and molecular genetics on diagnosis and treatment. In Freireich, E. J., ed. New approaches to the treatment of leukemia. Berlin: Springer-Verlag, 173.
   Google Scholar
• Bloomfield, C. D., Lawrence, D., Arthur, D. C., Berg, D. T., Schiffer, C. A. and Mayer, R. J. (1994). Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group, Blood, 84(suppl 1), 111a (abstract).
   PubMed Web of Science ®Google Scholar
• Miggiano, M. C., Gherlinzoni, F., Rosti, G., Bandini, G., Visani, G., Fiacchini, M., Ricci, P., Testoni, N., Motta, M. R., Geron, A., Rizzi, S., Belardinelli, A., Mangianti, S., Manfroi, S. and Tura, S. (1996). Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia, Leukemia, 10, 402.
   PubMed Web of Science ®Google Scholar
• Jourdan, E., Maraninchi, D., Reiffers, J., Archimbaud, E., Michallet, M., Haroussear, J. L., Ifrah, N., Rio, B., Guyotat, D., Guilhot, F., Attal, M., Leblond, V., Dauriac, C., Pico, J. L., Marit, G. and Blaise, D. (1995). Allogeneic bone marrow transplantation remains an efficient consolidation for adults with acute myeloid leukemia even when performed very soon after diagnosis (< 100 days), Leukemia, 9, 1068.
   PubMed Web of Science ®Google Scholar
• Rowe, J. M., Andersen, J. W., Mazza, J. J., Bennett, J. M., Paietta, E., Hayes, F. A., Oette, D., Cassileth, P. A., Stadtmauer, E. A. and Wiemik, P. H. (1995). A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Group, Blood, 86, 457.
   PubMed Web of Science ®Google Scholar
• Curtis, J. E., Minkin, S., Minden, M. D. and McCulloch, E. A. (1996). A role for paclitaxel in the combination chemotherapy of acute myeloblastic leukemia: preclinical cell culture studies, Br J Haematol, 95, 354.
   PubMed Web of Science ®Google Scholar